ライフサイエンスコーパス: cardiac pacing

1 enerator could represent a paradigm shift in cardiac pacing.

2 ub-Saharan Africa, completely lack access to cardiac pacing.

3 are common or controversial indications for cardiac pacing.

4 ), contributes significantly to neuronal and cardiac pacing.

5 ted by hyperpolarization, is a key player in cardiac pacing.

6 rome causes syncope, and symptoms respond to cardiac pacing.

7 cardiomyopathy despite early institution of cardiac pacing.

8 one that has eluded translation is long-term cardiac pacing.

9 be transferred to the capital for temporary cardiac pacing.

10 , metabolic vasodilation was assessed during cardiac pacing.

11 ber pacemakers for most patients who require cardiac pacing.

12 membrane polarization, demonstrated here for cardiac pacing.

13 ker replacement or a complication related to cardiac pacing.

14 atural history of heart failure due to rapid cardiac pacing.

15 s not necessarily imply a permanent need for cardiac pacing.

16 pacemakers and the termination of long-term cardiac pacing.

17 valuation of the methods and indications for cardiac pacing.

18 ment option given the recent developments in cardiac pacing.

19 cific application opportunities in temporary cardiac pacing.

20 y-like behaviour that was induced by optical cardiac pacing.

21 One group of dogs underwent 4 weeks of cardiac pacing (210 bpm for 3 weeks and 240 bpm during w

22 CHF was then induced by chronic rapid cardiac pacing and characterized by impaired cardiac fun

23 Implantable cardiac pacing and defibrillation devices are effective

24 th combined therapy consisting of continuous cardiac pacing and maximally tolerated beta-blocker ther

25 Rabbits with chronic cardiac pacing and sham operation were randomized to rec

26 function in biallelic mouse crosses: optical cardiac pacing and simultaneous cardiomyocyte Ca(2+) ima

27 Sympathetic nerve activity decreased with cardiac pacing and the decline was greater with AV than

28 Arterial pressure increased with cardiac pacing and was greater with AV than with ventric

29 dications for ICD therapy, no indication for cardiac pacing, and an LVEF of 40% or less, dual-chamber

30 only contribute to a better understanding of cardiac pacing but also may advance current efforts that

31 p-based approach to the development of local cardiac pacing capabilities in Sub-Saharan African natio

32 rovides a range of autonomous, rate-adaptive cardiac pacing capabilities, as demonstrated in rat, can

33 rks of miniature spinal cord stimulators and cardiac pacing devices in large animals via efficient an

34 As expected, cardiac pacing eliminated beat-to-beat RR interval varia

35 Programmed cardiac pacing evokes differential NA and NPY release in

36 Programmed cardiac pacing evokes homogeneous noradrenaline (NA) and

37 the translation of therapeutic TBX18-induced cardiac pacing faces safety challenges.

38 y injected TBX18 mRNA provided rate-adaptive cardiac pacing for one month that strongly correlated wi

39 The efficacy of cardiac pacing for prevention of syncopal recurrences in

40 A rethinking of the physiology of cardiac pacing has led to the concept that although atri

41 In heart failure, cardiac pacing has little, if any, variation in rate at

42 New indications for permanent cardiac pacing have been developed in recent years, with

43 itiated a multinational program to implement cardiac pacing in 14 countries in Sub-Saharan Africa (19

44 ble, and expanding clinical use of permanent cardiac pacing in a number of these conditions or syndro

45 e benefits and appropriate uses of permanent cardiac pacing in a variety of pathophysiologic states o

46 We sought to determine the incidence of cardiac pacing in our cardiac transplant population and

47 Prevention of syncope through permanent cardiac pacing in patients with bifascicular block (PRES

48 Indications for cardiac pacing in pediatric patients continue to expand.

49 ease and enabling beat-to-beat adaptation of cardiac pacing in response to physiological feedback.

50 In contrast, cardiac pacing in the 40 degree tilt position increased

51 Against expectations, however, cardiac pacing in the supine position significantly redu

52 ts with syncope of unknown origin, selecting cardiac pacing in those with a positive ATP test leads t

53 Rapid cardiac pacing increased myocardial oxidative stress as

54 Cardiac pacing-induced epicardial constriction was aboli

55 Cardiac pacing-induced reduction in coronary vascular re

56 Cardiac pacing is an effective treatment for patients wi

57 Cardiac pacing is effective for those patients with seve

58 electrode position for long-term transvenous cardiac pacing is in the apex of the right ventricle.

59 Cardiac pacing is poised to help millions of patients wo

60 ment of atrioventricular block, dual-chamber cardiac pacing is thought to confer a clinical benefit a

61 If or Ih, a key player in neuronal and cardiac pacing, is encoded by the hyperpolarization-acti

62 ormally functioning hearts and stimulated by cardiac pacing; it thus functioned as an ideal therapeut

63 inically used electronic implants, including cardiac pacing leads for epicardial monitoring and stimu

64 Discontinuation of cardiac pacing may be considered in certain patients.

65 nts with predominantly AF and secondary SND, cardiac pacing may be the mainstay of therapy for patien

66 icular outflow gradient at rest suggest that cardiac pacing may result in symptomatic and hemodynamic

67 han does ventricular pacing, indicating that cardiac pacing mode may influence sympathetic outflow si

68 Metabolic vasodilation was assessed during cardiac pacing (n = 19).

69 oventricular nodal disease, applications for cardiac pacing now include treatment of tachyarrhythmias

70 ves energy harvesting and storage as well as cardiac pacing on a large-animal scale.

71 t pacemaker is increasing, but the effect of cardiac pacing on long-term survival and functional vari

72 by partial reduction of coronary flow, rapid cardiac pacing, or brief ischemia-reperfusion of a remot

73 esuscitation, defibrillation, cardioversion, cardiac pacing, or treatments targeted at the underlying

74 Better prediction of cardiac pacing patients at risk of atrial fibrillation (

75 ation of similar patients and affect present cardiac-pacing policies.

76 We elected to use cardiac pacing rather than chronotropic drugs to minimiz

77 he aim of the study was to determine whether cardiac pacing reduces falls in older adults with cardio

78 Permanent cardiac pacing remains the only effective treatment for

79 Leadless cardiac pacing represents the future of cardiac pacing s

80 Temporary postoperative cardiac pacing requires devices with percutaneous leads

81 Dual-chamber AV cardiac pacing results in greater cardiac output and low

82 s, methods, and timing of the termination of cardiac pacing seems appropriate.

83 Despite early institution of cardiac pacing, some infants with CHB develop LV cardiom

84 These results suggest that high cardiac pacing stochasticity is likely to reduce the ris

85 less cardiac pacing represents the future of cardiac pacing systems, similar to the transition that o

86 ore amiodarone recipients required temporary cardiac pacing than did recipients of lidocaine or place

87 We used cardiac pacing to test the hypothesis that CM evolution

88 Cardiac pacing was effective in neurally mediated syncop

89 on Syncope of Uncertain Etiology (ISSUE-3), cardiac pacing was effective in reducing recurrence of s

90 The most common indication for cardiac pacing was permanent atrial fibrillation with at

91 dial diameter response to Ach, adenosine and cardiac pacing were measured in 32 patients with coronar

92 Four pairs of cardiac pacing wires were implanted on the serosa of the

93 minary studies evaluating the feasibility of cardiac pacing with a lead in the anterior mediastinum,